Tirzepatide discontinuation leads to weight regain in the majority of patients. Here are the scientific data and strategies to limit this phenomenon.
One of the most important questions for patients on Mounjaro is: what happens when treatment is stopped? Data from the SURMOUNT-4 study and observational studies provide clear, sometimes discouraging, answers, but also avenues to limit weight regain.
What the Scientific Data Say
The SURMOUNT-4 study is the primary reference. After 36 weeks of treatment, which resulted in a 20.9% body weight loss, patients randomized to placebo (tirzepatide discontinuation) regained an average of 14 percentage points of weight over 52 weeks. They nevertheless maintained a residual loss of approximately 10% compared to their baseline weight.
The kinematics of regain follow a predictable pattern: rapid in the first 3 months (approximately 1 kg/week), then progressively slower. One year after discontinuation, most patients had regained about 50 to 67% of the lost weight. This pattern is similar to that observed with semaglutide (STEP-1 extension study) and with long-term bariatric surgery.
Why is Weight Regain Almost Inevitable?
Obesity is a chronic disease with a strong biological component. Upon tirzepatide discontinuation, several mechanisms reactivate:
- Reactivation of appetite: without the action of GLP-1/GIP receptors, the satiety signal decreases and hunger returns to its pre-treatment level
- Reduced energy expenditure: the metabolism adapted to the new weight remains low, favoring storage
- Microbiota modification: the intestinal microbiome, modified during treatment, tends to return to its initial state
- Psychological factors: return of previous eating habits, stress, fatigue from nutritional vigilance
- Epigenetic programming: epigenetic modifications acquired during obesity persist after weight loss
Strategies to Limit Regain
Although regain is the rule, its extent can be significantly reduced:
- Maintenance of physical exercise: patients who maintain 200+ minutes of exercise/week regain 30-40% less weight
- High-protein diet: a high protein intake (1.2-1.5 g/kg) promotes satiety and limits muscle loss that accompanies regain
- Regular medical follow-up: quarterly consultations to detect regain early and consider resuming treatment
- Psychological support: behavioral therapy to anchor habit changes
- Gradual reduction: rather than abrupt discontinuation, some physicians attempt a gradual dose reduction (15→10→5 mg), although the efficacy of this approach has not yet been proven by studies
Is Lifelong Treatment Necessary?
The question of lifelong treatment is now at the heart of debates in obesity medicine. Scientific societies (EASO, Obesity Society) increasingly recognize obesity as a chronic disease requiring long-term treatment, similar to diabetes or hypertension. No one would suggest stopping an antihypertensive on the pretext that blood pressure has normalized; the same logic applies to anti-obesity treatments.
However, the cost (approximately €1,000/month in France, excluding reimbursement), potential very long-term effects (still unknown), and supply disruptions make this option complex. The search for maintenance strategies without continuous treatment remains an important objective.
Close monitoring after discontinuation is essential. The MounjaGO application allows you to monitor your weight daily and detect regain at its first signs, at which point resuming treatment is most effective.
FAQ: Weight Regain After Discontinuation
Can Mounjaro be resumed after discontinuation?
Yes. Tirzepatide remains effective upon treatment resumption. Titration should be restarted from the 2.5 mg dose to minimize gastrointestinal side effects.
Is regain faster than after a conventional diet?
Data suggest a similar regain rate in percentage (50-67% of lost weight at one year), but more significant in absolute terms because the initial loss is greater. The biological mechanisms are the same.
Are there patients who maintain their weight after discontinuation?
Yes, a minority (approximately 10-15%) maintain more than 80% of the weight loss one year after discontinuation. These patients are generally those who adopted the most significant lifestyle changes during treatment.